Regeneron shares fall 12% on disappointing melanoma trial data
Investing.com Gold reports: Regeneron shares fall 12% on disappointing melanoma trial data. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Regeneron shares fall 12% on disappointing melanoma trial data. Full body text was unavailable at ingest time, so this brief is based on headline context.